New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.

Abstract:

:Venous thromboembolism (VTE) is a major cause of morbidity, mortality, and healthcare expenditure. In the United States, approximately 0.1 % of the population experiences an initial VTE event each year. Anticoagulation therapy is the cornerstone of acute VTE treatment and for prevention of recurrent VTE events. Conventional anticoagulants, including heparin, low-molecular-weight heparins, fondaparinux, and vitamin K antagonists are widely used but have limitations. Newer oral anticoagulant agents, including direct thrombin inhibitors (e.g., dabigatran etexilate) and direct factor Xa inhibitors (e.g., rivaroxaban, apixaban, and edoxaban) have been developed to attempt to overcome some of the limitations of conventional anticoagulant therapy. These new oral agents have been evaluated for safety and efficacy in large, randomized clinical trials in the treatment and secondary prevention of VTE with results that are comparable to conventional therapy. Dabigatran, rivaroxaban, apixaban, and edoxaban are important new treatment options for patients with VTE. In this review, we compare these new agents and their associated clinical trials in VTE treatment.

journal_name

Drugs

journal_title

Drugs

authors

Dobesh PP,Fanikos J

doi

10.1007/s40265-014-0301-x

subject

Has Abstract

pub_date

2014-11-01 00:00:00

pages

2015-32

issue

17

eissn

0012-6667

issn

1179-1950

journal_volume

74

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

    abstract:UNLABELLED:Ceftriaxone is a parenteral third-generation cephalosporin with a long elimination half-life which permits once-daily administration. It has good activity against Streptococcus pneumoniae, methicillin-susceptible staphylococci, Haemophilus influenzae, Moraxella catarrhalis and Neisseria spp. Although active ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262070-00005

    authors: Lamb HM,Ormrod D,Scott LJ,Figgitt DP

    更新日期:2002-01-01 00:00:00

  • Gatifloxacin: a review of its use in the management of bacterial infections.

    abstract:UNLABELLED:Gatifloxacin is an 8-methoxy fluoroquinolone antibacterial agent. The drug has a broader spectrum of antibacterial activity than the older fluoroquinolones (e.g. ciprofloxacin) and shows good activity against many Gram-positive and Gram-negative pathogens, atypical organisms and some anaerobes. Notably, gati...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262010-00007

    authors: Perry CM,Ormrod D,Hurst M,Onrust SV

    更新日期:2002-01-01 00:00:00

  • Therapeutic experience with temocillin in peritonitis.

    abstract::The therapeutic efficacy of the new beta-lactam antibiotic, temocillin, was studied in 30 critically ill patients with peritonitis, abscesses, bronchopneumonia, and serious soft tissue infections. Patients were treated with temocillin Ig intravenously twice daily. The isolated pathogens comprised mainly Escherichia co...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500295-00042

    authors: Pfeiffer M,Fock RR

    更新日期:1985-01-01 00:00:00

  • Sotagliflozin: A Review in Type 1 Diabetes.

    abstract::Sotagliflozin (Zynquista™) is the first dual inhibitor of sodium-glucose co-transporter-1 and -2 (SGLT1 and 2). In the phase 3, inTANDEM 1-3 trials, adjunctive use of oral sotagliflozin (200 mg or 400 mg once daily) improved glycaemic control and reduced bodyweight and insulin requirements relative to placebo over 24 ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01230-w

    authors: Deeks ED

    更新日期:2019-12-01 00:00:00

  • Oral antidiabetic agents: current role in type 2 diabetes mellitus.

    abstract::Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term. The majority of patients are overweight or obese at diagnosis and will be unable to achieve or sustain near normoglycaemia without oral antidiabetic agents; a sizeable proportion of patients will eve...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565030-00005

    authors: Krentz AJ,Bailey CJ

    更新日期:2005-01-01 00:00:00

  • Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

    abstract::Zimelidine is a new antidepressant, which is structurally unrelated to the tricyclic and tetracyclic antidepressants. The pharmacological profile of zimelidine is different to that of other antidepressants in that it appears to owe the major part of its activity to the inhibition of serotonin uptake within the central...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198224030-00001

    authors: Heel RC,Morley PA,Brogden RN,Carmine AA,Speight TM,Avery GS

    更新日期:1982-09-01 00:00:00

  • Various administration forms of nitrates and their possibilities.

    abstract::This article reviews the development and pharmacokinetics of a number of new dosage formulations (e.g. transdermal patches and buccal tablets) and new active substances (e.g. isosorbide 5-mononitrate) which have recently been introduced to overcome some of the problems inherent in conventional formulations of organic ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198700334-00006

    authors: Jonsson UE

    更新日期:1987-01-01 00:00:00

  • An elucidation of the arachidonic acid cascade. Discovery of prostaglandins, thromboxane and leukotrienes.

    abstract::Arachidonic acid is normally stored in membrane-bound phospholipids and released by the action of phospholipases. Enzymatic conversion of released arachidonic acid into biologically active derivatives proceeds through one of several routes. Cyclo-oxygenase converts arachidonic acid to unstable cyclic endoperoxides fro...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198700331-00003

    authors: Samuelsson B

    更新日期:1987-01-01 00:00:00

  • Management of patients with advanced non-small cell lung cancer: current and emerging options.

    abstract::Systemic therapy for advanced non-small cell lung cancer (NSCLC) has evolved over the last two decades, with modest improvements in quality of life and overall survival. A plateau has been reached with traditional chemotherapy, and efforts are now being directed at developing molecularly targeted agents. To date, thre...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11532200-000000000-00000

    authors: Triano LR,Deshpande H,Gettinger SN

    更新日期:2010-01-01 00:00:00

  • Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension.

    abstract::Valsartan/hydrochlorothiazide is a fixed-dose (valsartan 80, 160 or 320mg plus hydrochlorothiazide 12.5 or 25mg) angiotensin II receptor blocker/diuretic drug combination indicated for the treatment of patients with essential hypertension not adequately controlled by monotherapy.There is ample evidence that valsartan/...

    journal_title:Drugs

    pub_type: 杂志文章,meta分析,评审

    doi:10.2165/00003495-200666140-00011

    authors: Wagstaff AJ

    更新日期:2006-01-01 00:00:00

  • Chemotherapeutic induction of labour. A rational approach.

    abstract::Induction of labour, defined as stimulation of uterine contractions before the spontaneous onset of labour, is indicated when the condition of the mother or fetus precludes awaiting the onset of spontaneous labour. In current medical practice, induction of labour comprises 2 phases: cervical priming and induction of c...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754010-00005

    authors: Xenakis EM,Piper JM

    更新日期:1997-07-01 00:00:00

  • Treatment of viral conjunctivitis with antiviral drugs.

    abstract::Viral conjunctivitis is one of the most common disorders observed in ophthalmic emergency departments, yet no established treatment exists. Lately, antiviral medications have been introduced into clinical practice; however, a systematic review focusing on their use and effectiveness in the treatment of viral conjuncti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11585330-000000000-00000

    authors: Skevaki CL,Galani IE,Pararas MV,Giannopoulou KP,Tsakris A

    更新日期:2011-02-12 00:00:00

  • Intravenous Minocycline: A Review in Acinetobacter Infections.

    abstract::Intravenous minocycline (Minocin®) is approved in the USA for use in patients with infections due to susceptible strains of Gram-positive and Gram-negative pathogens, including infections due to Acinetobacter spp. Minocycline is a synthetic tetracycline derivative that was originally introduced in the 1960s. A new int...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0636-6

    authors: Greig SL,Scott LJ

    更新日期:2016-10-01 00:00:00

  • Vasodilatation with pinacidil. Mode of action in rat resistance vessels.

    abstract::Pinacidil is a newly developed antihypertensive vasodilator, proposed to belong to the new group of smooth muscle relaxants, the K+ channel openers. The in vitro effects of pinacidil on induced tone, smooth muscle membrane potential and 86Rb and 42K efflux from rat resistance vessels (internal diameter about 200 micro...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198800367-00006

    authors: Videbaek LM,Aalkjaer C,Mulvany MJ

    更新日期:1988-01-01 00:00:00

  • Acamprosate: A Review of Its Use in Alcohol Dependence.

    abstract::Acamprosate (Campral(®), Aotal(®), Regtect(®)) is one of a limited number of pharmacological treatment options approved as an adjunct to psychosocial interventions to facilitate the maintenance of abstinence in alcohol-dependent patients. It has been used in Europe, the USA and other countries for many years and was r...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0423-9

    authors: Plosker GL

    更新日期:2015-07-01 00:00:00

  • White coat hypertension and related phenomena. A clinical approach.

    abstract::In this paper, several clinical problems associated with the diagnosis of hypertension are discussed. Blood pressure variability and reactivity are factors underlying the difficulties in the diagnosis of hypertension. These phenomena are interrelated and mixed. White coat hypertension (WCH), referring to the phenomeno...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199300462-00017

    authors: Ocón-Pujadas J,Mora-Maciá J

    更新日期:1993-01-01 00:00:00

  • Panic disorder. Pathophysiology and drug treatment.

    abstract::Advances over the past 2 decades in our understanding of the biology of panic disorder have paralleled a remarkable increase in the development of new pharmacological agents with antipanic effects. Although we can not presently use biological tests to help with our choice of therapeutic agent for individual patients, ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549030-00002

    authors: Johnson MR,Lydiard RB,Ballenger JC

    更新日期:1995-03-01 00:00:00

  • Lixisenatide: first global approval.

    abstract::The selective once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lyxumia(®)) is under development with Sanofi for the treatment of type 2 diabetes mellitus. Lixisenatide belongs to a class of GLP-1 compounds designed to mimic the endogenous hormone GLP-1. Native GLP-1 stimulates insulin...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0033-3

    authors: Elkinson S,Keating GM

    更新日期:2013-03-01 00:00:00

  • Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.

    abstract::Therapy for Gram-negative sepsis remains unsatisfactory despite a concerted effort to develop new treatments for this common, life-threatening syndrome. Current research continues on several fronts to improve the treatment options available to clinicians in the management of these critically ill patients. Recently, a ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855040-00002

    authors: Opal SM,Yu RL Jr

    更新日期:1998-04-01 00:00:00

  • Pimavanserin: First Global Approval.

    abstract::Pimavanserin (Nuplazid™) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions associated with Parkinson's disease psychosis. Up to 60 % of patients with ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0597-9

    authors: Markham A

    更新日期:2016-07-01 00:00:00

  • Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.

    abstract::As a consequence of disparities in access to and utilization of preventative healthcare, the incidence and death rates from cervical cancer remain substantial in the face of indisputable evidence that screening saves lives. While disparities persist, there will be an urgent need for research into the treatment of adva...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0481-z

    authors: Longoria TC,Tewari KS

    更新日期:2015-11-01 00:00:00

  • Valsartan/hydrochlorothiazide.

    abstract::Valsartan/hydrochlorothiazide (HCTZ) combines an angiotensin II AT1 receptor blocker with a thiazide diuretic to produce additive blood pressure reductions without major effects on heart rate. HCTZ did not significantly alter valsartan pharmacokinetics; during combination therapy, HCTZ pharmacokinetics differed from t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957050-00008

    authors: Langtry HD,McClellan KJ

    更新日期:1999-05-01 00:00:00

  • Overview of the management of acute gout and the role of adrenocorticotropic hormone.

    abstract::It is important to distinguish between therapy used to reduce acute inflammation in gout and therapy used to manage hyperuricaemia in patients with chronic gouty arthritis. This article discusses treatments for acute gout, emphasizing the use of corticotrophin (adrenocorticotropic hormone; ACTH) and the evidence on wh...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868040-00002

    authors: Schlesinger N

    更新日期:2008-01-01 00:00:00

  • Meningococcal groups C and Y and haemophilus B tetanus toxoid conjugate vaccine (HibMenCY-TT; MenHibrix(®)): a review.

    abstract::The meningococcal groups C and Y and Haemophilus b (Hib) tetanus toxoid conjugate vaccine (HibMenCY-TT) contains Neisseria meningitidis serogroup C and Y capsular polysaccharide antigens, and Hib capsular polysaccharide [polyribosyl-ribitol-phosphate (PRP)]. The HibMenCY-TT vaccine is available in the USA for use as a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0048-9

    authors: Perry CM

    更新日期:2013-05-01 00:00:00

  • Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

    abstract::Acyclovir (aciclovir) is a nucleoside antiviral drug with antiviral activity in vitro against members of the herpes group of DNA viruses. As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of acyclovir provide significant therapeutic benefit in genita...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198937030-00002

    authors: O'Brien JJ,Campoli-Richards DM

    更新日期:1989-03-01 00:00:00

  • Postoperative ileus: progress towards effective management.

    abstract::The pathogenesis of postoperative ileus (PI) is multifactorial, and includes activation of inhibitory reflexes, inflammatory mediators and opioids (endogenous and exogenous). Accordingly, various strategies have been employed to prevent PI. As single-modality treatment, continuous postoperative epidural analgesia incl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262180-00004

    authors: Holte K,Kehlet H

    更新日期:2002-01-01 00:00:00

  • Antacids and ulcer healing. A review of the evidence.

    abstract::There have been a number of controlled trials of antacids in the treatment of patients with peptic ulcer disease. As a general rule the size of studies has been small and there have been difficulties ensuring adequate binding, because of the formulation and taste of the antacids. Despite these difficulties, antacids a...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-199142020-00003

    authors: Walt RP,Langman MJ

    更新日期:1991-08-01 00:00:00

  • Migalastat: First Global Approval.

    abstract::Migalastat (Galafold™)-a small molecule drug developed by Amicus Therapeutics that restores the activity of specific mutant forms of α-galactosidase-has been approved for the treatment of Fabry disease in the EU in patients with amenable mutations. Fabry disease is a rare disorder that results in a deficiency or absen...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-016-0607-y

    authors: Markham A

    更新日期:2016-07-01 00:00:00

  • Sirolimus use in recipients of expanded criteria donor kidneys.

    abstract::With changing donor characteristics and the growing shortage in organ supply, renal transplant practitioners have sought to optimize the use of expanded criteria donor (ECD) kidneys, which have poorer outcomes than standard criteria donor (SCD) kidneys. The outcomes may represent an acceptable trade-off if ECD transpl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868001-00006

    authors: House AA,Nguan CY,Luke PP

    更新日期:2008-01-01 00:00:00

  • Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists.

    abstract::The introduction of medications that target specific proinflammatory cytokines has revolutionized the management of patients with rheumatoid arthritis. The agents that antagonize the effects of tumour necrosis factor (TNF)-alpha -- infliximab, etanercept and adalimumab -- have consistently shown very good efficacy for...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868050-00003

    authors: Lutt JR,Deodhar A

    更新日期:2008-01-01 00:00:00